Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors.
fenretinide (4-HPR)
liposomes
nanotechnology
retinoids
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
26 Aug 2021
26 Aug 2021
Historique:
received:
12
08
2021
revised:
23
08
2021
accepted:
24
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Retinoids are a class of natural and synthetic compounds derived from vitamin A. They are involved in several biological processes like embryogenesis, reproduction, vision, growth, inflammation, differentiation, proliferation, and apoptosis. In light of their important functions, retinoids have been widely investigated for their therapeutic applications. Thus far, their use for the treatment of several types of cancer and skin disorders has been reported. However, these therapeutic agents present several limitations for their widespread clinical translatability, i.e., poor solubility and chemical instability in water, sensitivity to light, heat, and oxygen, and low bioavailability. These characteristics result in internalization into target cells and tissues only at low concentration and, consequently, at an unsatisfactory therapeutic dose. Furthermore, the administration of retinoids causes severe side-effects. Thus, in order to improve their pharmacological properties and circulating half-life, while minimizing their off-target uptake, various retinoids delivery systems have been recently developed. This review intends to provide examples of retinoids-loaded nano-delivery systems for cancer treatment. In particular, the use and the therapeutic results obtained by using fenretinide-loaded liposomes against neuroectodermal-derived tumors, such as melanoma, in adults, and neuroblastoma, the most common extra-cranial solid tumor of childhood, will be discussed.
Identifiants
pubmed: 34577553
pii: ph14090854
doi: 10.3390/ph14090854
pmc: PMC8466194
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 18474
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 24397
Références
J Histochem Cytochem. 2011 Jan;59(1):47-59
pubmed: 21339174
Curr Opin Cell Biol. 2019 Dec;61:110-116
pubmed: 31476530
Anticancer Res. 2015 Dec;35(12):6425-9
pubmed: 26637852
Colloids Surf B Biointerfaces. 2017 Feb 1;150:408-416
pubmed: 27829536
Curr Med Chem. 2007;14(29):3070-8
pubmed: 18220743
Carcinogenesis. 2005 Feb;26(2):417-27
pubmed: 15498786
Cancer Res. 2003 Jan 1;63(1):86-92
pubmed: 12517782
Chem Rev. 2014 Jan 8;114(1):194-232
pubmed: 23905688
Cancer Res. 2001 Jan 1;61(1):2-7
pubmed: 11196162
Exp Biol Med (Maywood). 2017 Jun;242(11):1178-1184
pubmed: 28429653
Expert Opin Drug Deliv. 2008 Mar;5(3):343-51
pubmed: 18318655
J Control Release. 2021 Apr 10;332:127-147
pubmed: 33609621
J Exp Clin Cancer Res. 2019 Aug 22;38(1):373
pubmed: 31439019
Molecules. 2017 Aug 23;22(9):
pubmed: 28832535
Mol Ther. 2011 Jun;19(6):1131-40
pubmed: 21487394
Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):415-426
pubmed: 30539216
Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5
pubmed: 20304019
Nanomedicine. 2013 Jul;9(5):675-85
pubmed: 23219878
Cancer Lett. 2003 Jul 18;197(1-2):185-92
pubmed: 12880980
Biomaterials. 2015 Nov;68:89-99
pubmed: 26276694
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
J Control Release. 2013 Sep 10;170(2):233-41
pubmed: 23714122
Int J Pharm. 2007 Jul 18;339(1-2):246-50
pubmed: 17412536
Int J Oncol. 1993 Nov;3(5):909-15
pubmed: 21573452
J Dermatolog Treat. 2017 Dec;28(8):684-696
pubmed: 28318351
Small. 2019 Mar;15(10):e1804591
pubmed: 30706636
Dev Dyn. 2015 Mar;244(3):311-22
pubmed: 25382669
Nat Biotechnol. 2005 Dec;23(12):1517-26
pubmed: 16333296
J Control Release. 2006 Feb 21;110(3):514-21
pubmed: 16360957
J Clin Oncol. 1993 Oct;11(10):2036-42
pubmed: 8410127
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Cancer Chemother Pharmacol. 1979;3(4):207-15
pubmed: 394876
Expert Rev Anticancer Ther. 2010 Nov;10(11):1811-23
pubmed: 21080806
Drugs. 2019 Nov;79(17):1905-1909
pubmed: 31713811
Drug Discov Today. 2002 Dec 1;7(23):1165-74
pubmed: 12547017
Eur J Dermatol. 2015 Sep-Oct;25(5):384-91
pubmed: 26069148
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
pubmed: 1763060
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun;163(2):122-131
pubmed: 30967685
Cancer Res. 2006 Oct 15;66(20):10073-82
pubmed: 17047071
Small. 2020 May;16(20):e1906426
pubmed: 32323486
Int J Cancer. 1999 Apr 12;81(2):262-7
pubmed: 10188729
Cancer Treat Rev. 2005 Feb;31(1):27-34
pubmed: 15707702
J Cell Biochem Suppl. 1994;20:55-62
pubmed: 7616753
Macromol Biosci. 2014 Mar;14(3):369-79
pubmed: 24115498
Cancer Res. 2000 Feb 1;60(3):722-7
pubmed: 10676659
Int J Cancer. 2003 May 1;104(5):559-67
pubmed: 12594810
Nat Commun. 2020 Aug 26;11(1):4265
pubmed: 32848154
Nat Genet. 1999 Apr;21(4):444-8
pubmed: 10192400
Curr Oncol Rep. 2000 May;2(3):263-70
pubmed: 11122852
J Drug Target. 2008 Dec;16(10):758-72
pubmed: 18985508
Cancer Res. 1995 Feb 15;55(4):853-61
pubmed: 7850799
Expert Opin Drug Deliv. 2009 May;6(5):465-83
pubmed: 19413455
J Biol Chem. 1996 Dec 6;271(49):31723-8
pubmed: 8940196
J Control Release. 2010 Jul 1;145(1):66-73
pubmed: 20346382
FASEB J. 1996 Jul;10(9):1014-24
pubmed: 8801162
Clin Cancer Res. 2003 Oct 1;9(12):4595-605
pubmed: 14555535
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
J Exp Clin Cancer Res. 2021 Jun 2;40(1):180
pubmed: 34078433
BMC Cancer. 2018 Nov 1;18(1):1059
pubmed: 30384831
Med Res Rev. 2012 Sep;32(5):1078-91
pubmed: 21287572
Pancreatology. 2017 Jul - Aug;17(4):514-522
pubmed: 28601475
Apoptosis. 2001 Oct;6(5):377-88
pubmed: 11483862
Small. 2011 May 23;7(10):1432-9
pubmed: 21506266
Proc Natl Acad Sci U S A. 1978 Sep;75(9):4194-8
pubmed: 279908
Biochim Biophys Acta. 1991 Sep 30;1068(2):133-41
pubmed: 1911826
Biomed Pharmacother. 2014 Jul;68(6):737-43
pubmed: 25108345
Cancer Res. 1987 Feb 15;47(4):1098-104
pubmed: 3100030
Drug Metab Pers Ther. 2019 Feb 1;34(1):
pubmed: 30707682
Curr Pharm Des. 2005;11(28):3655-60
pubmed: 16305501
J Control Release. 2013 Sep 28;170(3):445-51
pubmed: 23792118
Genesis. 2008 Nov;46(11):640-56
pubmed: 19003929
Nanoscale Res Lett. 2013 Feb 22;8(1):102
pubmed: 23432972
Dev Neurobiol. 2010 Oct;70(12):796-812
pubmed: 20683859
Methods Mol Biol. 2017;1522:17-22
pubmed: 27837527
Int J Dev Biol. 2003;47(7-8):531-9
pubmed: 14756329
J Neurobiol. 2006 Jun;66(7):606-30
pubmed: 16688755
Ann N Y Acad Sci. 2004 Dec;1028:104-12
pubmed: 15650236
Int J Dev Biol. 2011;55(4-5):547-55
pubmed: 21858775
Anticancer Res. 2017 Nov;37(11):5975-5981
pubmed: 29061776
Eur J Pharm Biopharm. 2019 Oct;143:80-90
pubmed: 31446044
Eur J Cancer. 1991;27(2):138-41
pubmed: 1827276
Drug Resist Updat. 2016 Nov;29:90-106
pubmed: 27912846
Cancer Res. 2003 Nov 1;63(21):7400-9
pubmed: 14612539
Clin Cancer Res. 2000 May;6(5):1900-8
pubmed: 10815914
Annu Rev Cell Dev Biol. 2012;28:687-717
pubmed: 22804578
Br J Haematol. 2010 Jul;150(2):158-69
pubmed: 20507312
Nature. 1976 Sep 9;263(5573):110-3
pubmed: 987541
Wiley Interdiscip Rev Dev Biol. 2017 Jan;6(1):
pubmed: 27906497
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Dev Biol. 2018 Dec 1;444 Suppl 1:S36-S46
pubmed: 29852131
J Pharm Pharmacol. 2019 Aug;71(8):1185-1198
pubmed: 31049986
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Curr Opin Pediatr. 2019 Feb;31(1):14-20
pubmed: 30480556
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
pubmed: 23036225
Med Toxicol Adverse Drug Exp. 1988 Jul-Aug;3(4):273-88
pubmed: 3054426
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
pubmed: 19225113
Int J Cancer. 1999 Apr 12;81(2):268-74
pubmed: 10188730
Annu Rev Cell Dev Biol. 2009;25:221-51
pubmed: 19575677
Eur J Cancer. 1998 Feb;34(3):428-9
pubmed: 9640237
J Clin Oncol. 1995 Apr;13(4):894-901
pubmed: 7707116